Melanoma Bridge 2014

Oncology Meeting Resources

03 Dec - 06 Dec, Naples, Italy

Melanoma Bridge aims at sharing clinical or basic interest in the immunology and the biology of the cancer microenvironment.

On this page, you may download the PDFs of presentations given at Melanoma Bridge 2014 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Useful links

Presenter Presentation title Session title
Paolo A. Ascierto Welcome and introduction Opening Ceremony
Giorgio Parmiani Award lecture of Fondazione Melanoma: Melanoma vaccines: New targets and combination therapy Opening Ceremony
Paul Lorigan Clinical trial and real world evidence Opening Ceremony
Francesco De Lorenzo A pan-European policy strategy to overcome inequalities: Impact on melanoma Patients meet the melanoma experts
Bettina Ryll Patient-centered clinical research in Melanoma Patients meet the melanoma experts
Michael Davies The multi-faced roles of the PI3K-AKT pathway in melanoma Molecular and immuno advances
Alistair Cochran Molecular enhancement of sentinel node evaluation Molecular and immuno advances
Sandra Demaria Mechanisms of synergy of radiotherapy and immunotherapy Molecular and immuno advances
Michael Atkins Beyond BRAFi/MEK/i: Combination and sequencing approaches for patients with BRAF mutant melanoma Combination therapies
Jeff Sosman MEK + CDK4 a regimen for non-BRAF V6000 melanoma Combination therapies
Igor Puzanov Combining targeted drugs and immunotherapy for melanoma Combination therapies
Mario Sznol Combination therapies based on PD-1/PDL-1 pathway antagonists Combination therapies
Silvia Formenti Combining radiation therapy with immunotherapy: Clinical translation Combination therapies
Nicola Mozzillo Surgery in the combination therapies era Combination therapies
Paolo A. Ascierto coBRIM: A Phase 3, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib + Cobimetinib in Previously Untreated BRAFV600 Mutation–Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma (NCT01689519) Combination therapies